Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06827145 | Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC | PHASE2 | ACTIVE NOT_RECRUITING | 30 | — | — | Oct 14, 2024 | Sep 1, 2028 | Feb 14, 2025 | 1 | China |
From the first treatment to the date of first documentation of disease progression, or death due to any cause
| Arm | Type | Description |
|---|---|---|
| Experimental Arm | EXPERIMENTAL | All patients received oral Vebreltinib 100mg BID plus Osimertinib 80mg once daily. |
| Name | Type | Description |
|---|---|---|
| Vebreltinib | DRUG | Vebreltinib 100mg oral BID |
| Osimertinib | DRUG | Osimertinib 80mg oral once daily. |
Inclusion Criteria: * 1\. Signed an informed consent form. 2\. Patients aged ≥18. 3\. Histologically or cytologically confirmed locally or metastatic NSCLC. 4.EGFR 21 L858R mutation. 5.at least one measurable lesion according to RECIST 1.1 criteria. 6.ECOG PS 0-1. 7.appropriate or...